229 related articles for article (PubMed ID: 32321318)
1. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
Sarkozy C; Ribrag V
Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
Gribbin C; Chen J; Martin P; Ruan J
Leuk Lymphoma; 2024 Jan; 65(1):1-13. PubMed ID: 37800170
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling and management of mantle cell lymphoma.
Ruan J
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
[TBL] [Abstract][Full Text] [Related]
4. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
El Halabi L; Ghez D; Ribrag V
Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
[TBL] [Abstract][Full Text] [Related]
5. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in genomics and therapeutics in mantle cell lymphoma.
Lu T; Zhang J; McCracken JM; Young KH
Cancer Treat Rev; 2024 Jan; 122():102651. PubMed ID: 37976759
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.
Saleh K; Cheminant M; Chiron D; Burroni B; Ribrag V; Sarkozy C
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804999
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
Klener P
Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
[TBL] [Abstract][Full Text] [Related]
9. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.
Nadeu F; Martin-Garcia D; Clot G; Díaz-Navarro A; Duran-Ferrer M; Navarro A; Vilarrasa-Blasi R; Kulis M; Royo R; Gutiérrez-Abril J; Valdés-Mas R; López C; Chapaprieta V; Puiggros M; Castellano G; Costa D; Aymerich M; Jares P; Espinet B; Muntañola A; Ribera-Cortada I; Siebert R; Colomer D; Torrents D; Gine E; López-Guillermo A; Küppers R; Martin-Subero JI; Puente XS; Beà S; Campo E
Blood; 2020 Sep; 136(12):1419-1432. PubMed ID: 32584970
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Nastoupil LJ; Koff JL; Flowers CR
Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
[TBL] [Abstract][Full Text] [Related]
11. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
12. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
13. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
Che Y; Liu Y; Yao Y; Hill HA; Li Y; Cai Q; Yan F; Jain P; Wang W; Rui L; Wang M
Blood Cancer J; 2023 Feb; 13(1):27. PubMed ID: 36797243
[TBL] [Abstract][Full Text] [Related]
14. Novel agents in mantle cell lymphoma.
Tucker D; Rule S
Expert Rev Anticancer Ther; 2017 Jun; 17(6):491-506. PubMed ID: 28480764
[TBL] [Abstract][Full Text] [Related]
15. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
16. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
17. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
18. Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.
Tang T; Martin P
Curr Hematol Malig Rep; 2014 Sep; 9(3):254-61. PubMed ID: 25023397
[TBL] [Abstract][Full Text] [Related]
19. Current status of targeted therapies for mantle cell lymphoma.
Chang JE; Kahl BS
Drugs; 2011 Dec; 71(17):2307-26. PubMed ID: 22085387
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]